Drs Banu Arun and Filipa Lynce discuss what the future holds for antibody-drug conjugates in different metastatic breast cancer subgroups, including efficacy, strategies, and toxicities.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982644). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

New Antibody-Drug Conjugates (ADCs) in Breast Cancer -- an Overview of ADCs Recently Approved and in Later Stages of Development https://pubmed.ncbi.nlm.nih.gov/36046357/

Stage 4 (Advanced or Metastatic) Breast Cancer https://nbcf.org.au/about-breast-cancer/diagnosis/stage-4-advanced-or-metastatic-breast-cancer/

HER2/neu Test https://www.cancer.gov/publications/dictionaries/cancer-terms/def/her2-neu-test

Triple Negative Breast Cancer: A Thorough Review of Biomarkers https://pubmed.ncbi.nlm.nih.gov/31927455/

Management of Hormone Receptor-Positive, HER2-Negative Early Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32546323/

BRCA Gene Mutations: Cancer Risk and Genetic Testing https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#what-are-brca1-and-brca2

Payloads for Antibody–Drug Conjugates https://pubs.acs.org/doi/10.1021/acs.oprd.2c00227

Bystander Effect of Antibody-Drug Conjugates: Fact or Fiction? https://pubmed.ncbi.nlm.nih.gov/35305211/

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/30516102/

Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35320644/

CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/21147694/

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33882206/

TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+/HER2- Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32223649/

The Emerging CDK4/6 Inhibitor for Breast Cancer Treatment https://pubmed.ncbi.nlm.nih.gov/35251463/

Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases https://pubmed.ncbi.nlm.nih.gov/36074155/

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/31881136/

Datopotamab Deruxtecan, a Novel TROP2-Directed Antibody-Drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells https://pubmed.ncbi.nlm.nih.gov/34413126/

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34404686/

PARP and PARG Inhibitors in Cancer Treatment https://pubmed.ncbi.nlm.nih.gov/32029455/